Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease.

Prokopienko AJ, West RE 3rd, Schrum DP, Stubbs JR, Leblond FA, Pichette V, Nolin TD.

Sci Rep. 2019 Nov 4;9(1):15901. doi: 10.1038/s41598-019-52032-9.

2.

PrEP Use Among Female Sex Workers: No Evidence for Risk Compensation.

Giguère K, Béhanzin L, Guédou FA, Talbot D, Leblond FA, Goma-Matsétsé E, Zannou DM, Affolabi D, Kêkê RK, Gangbo F, Bachabi M, Alary M.

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):257-264. doi: 10.1097/QAI.0000000000002134.

3.

A novel nested polymerase chain reaction targeting the testis-specific protein Y-encoded family of genes for high sensitivity of recent semen exposure detection: Comparison with four other assays of semen detection.

Giguère K, Leblond FA, Goma-Matsétsé E, Dave V, Béhanzin L, Guédou FA, Alary M.

PLoS One. 2019 Jul 25;14(7):e0220326. doi: 10.1371/journal.pone.0220326. eCollection 2019.

4.

PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice.

Thibodeau JF, Simard JC, Holterman CE, Blais A, Cloutier MP, Medeiros T, Leduc M, Grouix B, Leblond FA, Burger D, Hébert RL, Kennedy CRJ, Gagnon L.

Clin Sci (Lond). 2019 Jul 22;133(14):1587-1602. doi: 10.1042/CS20190479. Print 2019 Jul 31.

PMID:
31308217
5.

Biological Validation of Self-Reported Unprotected Sex and Comparison of Underreporting Over Two Different Recall Periods Among Female Sex Workers in Benin.

Giguère K, Béhanzin L, Guédou FA, Leblond FA, Goma-Matsétsé E, Zannou DM, Affolabi D, Kêkê RK, Gangbo F, Bachabi M, Alary M.

Open Forum Infect Dis. 2019 Jan 9;6(2):ofz010. doi: 10.1093/ofid/ofz010. eCollection 2019 Feb.

6.

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.

Grouix B, Sarra-Bournet F, Leduc M, Simard JC, Hince K, Geerts L, Blais A, Gervais L, Laverdure A, Felton A, Richard J, Ouboudinar J, Gagnon W, Leblond FA, Laurin P, Gagnon L.

J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. doi: 10.1124/jpet.118.250068. Epub 2018 Aug 9.

PMID:
30093459
7.

Rationale for the administration of systemic 5-FU in combination with heated intraperitonal oxaliplatin.

Badrudin D, Sideris L, Leblond FA, Pichette V, Cloutier AS, Drolet P, Dubé P.

Surg Oncol. 2018 Jun;27(2):275-279. doi: 10.1016/j.suronc.2018.05.004. Epub 2018 May 6.

PMID:
29937182
8.

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.

Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P.

Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16.

9.

Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model.

Badrudin D, Sideris L, Perrault-Mercier C, Hubert J, Leblond FA, Dubé P.

J Surg Oncol. 2018 May;117(6):1318-1322. doi: 10.1002/jso.24960. Epub 2018 Jan 22.

PMID:
29355970
10.

Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes.

Dion F, Dumayne C, Henley N, Beauchemin S, Arias EB, Leblond FA, Lesage S, Lefrançois S, Cartee GD, Pichette V.

PLoS One. 2017 May 1;12(5):e0176650. doi: 10.1371/journal.pone.0176650. eCollection 2017.

11.

Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents.

Mawad H, Laurin LP, Naud JF, Leblond FA, Henley N, Vallée M, Pichette V, Leblanc M.

Biomark Insights. 2016 Jun 29;11:91-4. doi: 10.4137/BMI.S39199. eCollection 2016.

12.

Effects of Chronic Renal Failure on Brain Cytochrome P450 in Rats.

Naud J, Harding J, Lamarche C, Beauchemin S, Leblond FA, Pichette V.

Drug Metab Dispos. 2016 Aug;44(8):1174-9. doi: 10.1124/dmd.116.070052. Epub 2016 Jun 6.

PMID:
27271372
13.

Electrocautery effect on intestinal vascularisation in a murine model.

Tremblay JF, Sideris L, Leblond FA, Trépanier JS, Badrudin D, Drolet P, Mitchell A, Dubé P.

Int J Hyperthermia. 2016 Sep;32(6):643-7. doi: 10.1080/02656736.2016.1181276. Epub 2016 Jun 7.

PMID:
27270101
14.

Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model.

Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, Hubert J, Leblond FA, Sideris L, Dubé P.

Surg Oncol. 2016 Dec;25(4):435-440. doi: 10.1016/j.suronc.2016.05.014. Epub 2016 May 20.

PMID:
27251757
15.

Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Alshogran OY, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

J Chromatogr Sci. 2016 Apr;54(4):554-60. doi: 10.1093/chromsci/bmv186. Epub 2015 Dec 11.

16.

In Vitro and In Vivo Mechanistic Studies toward Understanding the Role of 1-Aminobenzotriazole in Rat Drug-Drug Interactions.

Boily MO, Chauret N, Laterreur J, Leblond FA, Boudreau C, Duquet MC, Lévesque JF, Ste-Marie L, Pichette V.

Drug Metab Dispos. 2015 Dec;43(12):1960-5. doi: 10.1124/dmd.115.066357. Epub 2015 Oct 5.

PMID:
26438628
17.

[Drug pharmacokinetics in renal failure: What's new?].

Naud J, Dumayne C, Nolin TD, Leblond FA, Pichette V.

Nephrol Ther. 2015 Jun;11(3):144-51. doi: 10.1016/j.nephro.2014.12.006. Epub 2015 Apr 7. Review. French.

PMID:
25861715
18.

Effect of experimental kidney disease on the functional expression of hepatic reductases.

Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

Drug Metab Dispos. 2015 Jan;43(1):100-6. doi: 10.1124/dmd.114.061150. Epub 2014 Oct 20.

PMID:
25332430
19.

Determination of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: application to in vitro enzyme kinetic studies.

Alshogran OY, Ocque AJ, Zhao J, Day BW, Leblond FA, Pichette V, Nolin TD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:63-8. doi: 10.1016/j.jchromb.2013.11.014. Epub 2013 Nov 14.

PMID:
24291722
20.

Bicarbonates for the prevention of postoperative renal failure in endovascular aortic aneurysm repair: a randomized pilot trial.

Brulotte V, Leblond FA, Elkouri S, Thérasse E, Pichette V, Beaulieu P.

Anesthesiol Res Pract. 2013;2013:467326. doi: 10.1155/2013/467326. Epub 2013 Jun 12.

21.

Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment.

Manuguerra-Gagné R, Boulos PR, Ammar A, Leblond FA, Krosl G, Pichette V, Lesk MR, Roy DC.

Stem Cells. 2013 Jun;31(6):1136-48. doi: 10.1002/stem.1364.

22.

Calcidiol deficiency in CKD patients: the role of reduced liver synthesis.

Pichette V, Ouimet D, Leblond FA.

Am J Kidney Dis. 2012 Dec;60(6):1049; author reply 1049. doi: 10.1053/j.ajkd.2012.07.027. No abstract available.

PMID:
23141998
23.

[Kidney injury biomarkers].

Gueguen Y, Rouas C, Leblond FA.

Nephrol Ther. 2012 Jun;8(3):146-55. doi: 10.1016/j.nephro.2012.02.004. Epub 2012 Apr 3. Review. French.

PMID:
22475789
24.

Current understanding of drug disposition in kidney disease.

Naud J, Nolin TD, Leblond FA, Pichette V.

J Clin Pharmacol. 2012 Jan;52(1 Suppl):10S-22S. doi: 10.1177/0091270011413588. Review.

PMID:
22232747
25.

Effects of chronic renal failure on brain drug transporters in rats.

Naud J, Laurin LP, Michaud J, Beauchemin S, Leblond FA, Pichette V.

Drug Metab Dispos. 2012 Jan;40(1):39-46. doi: 10.1124/dmd.111.041145. Epub 2011 Oct 3.

PMID:
21969519
26.

Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.

Naud J, Michaud J, Beauchemin S, Hébert MJ, Roger M, Lefrancois S, Leblond FA, Pichette V.

Drug Metab Dispos. 2011 Aug;39(8):1363-9. doi: 10.1124/dmd.111.039115. Epub 2011 Apr 27.

PMID:
21525170
27.

Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.

Piché N, Leblond FA, Sidéris L, Pichette V, Drolet P, Fortier LP, Mitchell A, Dubé P.

Ann Surg. 2011 Jul;254(1):138-44. doi: 10.1097/SLA.0b013e3182193143.

PMID:
21494122
28.

Reduced hepatic synthesis of calcidiol in uremia.

Michaud J, Naud J, Ouimet D, Demers C, Petit JL, Leblond FA, Bonnardeaux A, Gascon-Barré M, Pichette V.

J Am Soc Nephrol. 2010 Sep;21(9):1488-97. doi: 10.1681/ASN.2009080815. Epub 2010 Jul 1.

29.

Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.

Dani M, Boisvert C, Michaud J, Naud J, Lefrançois S, Leblond FA, Pichette V.

Drug Metab Dispos. 2010 Mar;38(3):357-60. doi: 10.1124/dmd.109.029991. Epub 2009 Dec 9.

PMID:
20007296
30.

ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J.

J Am Soc Nephrol. 2009 Oct;20(10):2269-76. doi: 10.1681/ASN.2009010082. Epub 2009 Aug 20.

31.

Effect of hemodialysis on hepatic cytochrome P450 functional expression.

Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, Pichette V.

J Pharmacol Sci. 2008 Oct;108(2):157-63. Epub 2008 Oct 9.

32.

Downregulation of hepatic acetylation of drugs in chronic renal failure.

Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A, Guillemette C, Sim E, Pichette V.

J Am Soc Nephrol. 2008 Jul;19(7):1352-9. doi: 10.1681/ASN.2007090974. Epub 2008 Apr 16. No abstract available.

33.

Emerging evidence of the impact of kidney disease on drug metabolism and transport.

Nolin TD, Naud J, Leblond FA, Pichette V.

Clin Pharmacol Ther. 2008 Jun;83(6):898-903. doi: 10.1038/clpt.2008.59. Epub 2008 Apr 2. Review.

PMID:
18388866
34.

Effects of chronic renal failure on liver drug transporters.

Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V.

Drug Metab Dispos. 2008 Jan;36(1):124-8. Epub 2007 Oct 16.

PMID:
17940133
35.

Down-regulation of intestinal drug transporters in chronic renal failure in rats.

Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, Pichette V.

J Pharmacol Exp Ther. 2007 Mar;320(3):978-85. Epub 2006 Nov 29.

PMID:
17135344
36.

Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure.

Michaud J, Naud J, Chouinard J, Désy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V.

J Am Soc Nephrol. 2006 Nov;17(11):3041-8. Epub 2006 Oct 4.

37.

Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine.

Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, Pichette V.

J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):209-13. Epub 2006 Aug 4.

PMID:
16979351
38.

Evidence that the mouse osteocalcin-related gene does not encode nephrocalcin.

Petrucci M, Paquette Y, Leblond FA, Pichette V, Bonnardeaux A.

Nephron Exp Nephrol. 2006;104(4):e140-6. Epub 2006 Aug 10.

PMID:
16902318
39.

Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450.

Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V.

Br J Pharmacol. 2005 Apr;144(8):1067-77.

40.
41.

Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers.

Dusseault J, Leblond FA, Robitaille R, Jourdan G, Tessier J, Ménard M, Henley N, Hallé JP.

Biomaterials. 2005 May;26(13):1515-22.

PMID:
15522753
42.

Drug metabolism in chronic renal failure.

Pichette V, Leblond FA.

Curr Drug Metab. 2003 Apr;4(2):91-103. Review.

PMID:
12678690
43.

Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.

Guévin C, Michaud J, Naud J, Leblond FA, Pichette V.

Br J Pharmacol. 2002 Dec;137(7):1039-46.

44.

Downregulation of intestinal cytochrome p450 in chronic renal failure.

Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, Pichette V.

J Am Soc Nephrol. 2002 Jun;13(6):1579-85.

45.

Decreased in vivo metabolism of drugs in chronic renal failure.

Leblond FA, Giroux L, Villeneuve JP, Pichette V.

Drug Metab Dispos. 2000 Nov;28(11):1317-20.

PMID:
11038159
46.
47.

Studies on smaller (approximately 315 microM) microcapsules: IV. Feasibility and safety of intrahepatic implantations of small alginate poly-L-lysine microcapsules.

Leblond FA, Simard G, Henley N, Rocheleau B, Huet PM, Hallé JP.

Cell Transplant. 1999 May-Jun;8(3):327-37.

PMID:
10442745
48.

Alginate-poly-L-lysine microcapsule biocompatibility: a novel RT-PCR method for cytokine gene expression analysis in pericapsular infiltrates.

Robitaille R, Leblond FA, Henley N, Prud'homme GJ, Drobetsky E, Hall JP.

J Biomed Mater Res. 1999 Jun 5;45(3):223-30.

PMID:
10397980
49.

Studies on small (<350 microm) alginate-poly-L-lysine microcapsules. III. Biocompatibility Of smaller versus standard microcapsules.

Robitaille R, Pariseau JF, Leblond FA, Lamoureux M, Lepage Y, Hallé JP.

J Biomed Mater Res. 1999 Jan;44(1):116-20.

PMID:
10397911
50.

Supplemental Content

Loading ...
Support Center